Nedaplatin Salvage Chemotherapy for Cervical Cancer
نویسندگان
چکیده
منابع مشابه
Nedaplatin: a cisplatin derivative in cancer chemotherapy
Nedaplatin, a cisplatin analog, has been developed to decrease the toxicities induced by cisplatin, such as nephrotoxicity and gastrointestinal toxicity. The dose of nedaplatin is determined by body surface area, not by the area under the curve (AUC). The recommended therapeutic dose is 80-100 mg/m(2), although the pharmacokinetic profile of nedaplatin is similar to that of carboplatin. In our ...
متن کاملNedaplatin: A Radiosensitizing Agent for Patients with Cervical Cancer
Despite the recent advances in the management of cervical cancer using cisplatin-based concurrent chemoradiotherapy, substantial treatment failure still occurs, especially in advanced-stage patients and early-stage cervical cancer patients with high-risk prognostic factors. Therefore, efforts to further improve the survival and quality of life of these patients are necessary. Nedaplatin (cis-di...
متن کاملChemotherapy for Cervical Cancer
The Gynecologic Oncology Group (GOG) is a large organization with collaboration among institutions in the USA. The group has been active in many important trials involving gynecologic cancers. Until March 2011, 477 protocols were completed (82 phase III, 311 phase II, and other phase I, staging or special studies) while 50 are currently active (1). From the first (GOG 1) to the last trial (GOG ...
متن کاملSalvage chemotherapy for metastatic breast cancer.
Salvage chemotherapy for metastatic breast cancer includes regimens for hormonal responsive patients and patients refractory to cyclophosphamide, methotrexate, and fluorouracil (CMF) or fluorouracil, doxorubicin, and cyclophosphamide (FAC). For hormone responsive patients, progestins, aminoglutethimide with hydrocortisone, and androgens provide second-line therapy and produce objective remissio...
متن کاملGemcitabine Plus Nedaplatin as Salvage Therapy for Metastatic Urothelial Carcinoma
This study was conducted to evaluate the effectiveness of a combination of gemcitabine and nedaplatin therapy among patients with metastatic urothelial carcinoma previously treated with two lines of chemotherapy. Between February 2009 and August 2013, 30 patients were treated with gemcitabine and paclitaxel as a second-line chemotherapy. All had received a first-line chemotherapy consisting of ...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Asian Pacific Journal of Cancer Prevention
سال: 2015
ISSN: 1513-7368
DOI: 10.7314/apjcp.2015.16.8.3159